Seoul St. Mary's Hospital, which established the first blood hospital in Korea, revealed the results of the treatment of ...

Patients with relapsed/refractory (R/R) multiple myeloma and lower socioeconomic status reported significantly worse quality of life and a higher burden of symptoms, according to Francesco Sparano, ...

A "Trojan horse" therapy that sneaks toxic drugs inside cancer cells is being made available on the NHS in England in a world ...

A talk with study author on a new combination of acimtamig and an allogeneic natural killer cell product that shows safety ...

Renal failure in multiple myeloma typically occurs when the kidneys fail to filter waste products from the blood, leading to ...

The dramatic bend in the curve of cancer deaths didn’t happen by accident — it’s the compound interest of three revolutions.

In An Exercise in Uncertainty, Jon Gluck traces decades of waiting, watching, enduring experimental treatment, and ...

Phase 1 trial demonstrates encouraging clinical activity of investigational immunotherapy for relapsed or refractory multiple myeloma ...

Oral presentation of CARTITUDE-1 study data showcases long-term outcomes after a single infusion of CARVYKTI ® with one-third of patients with relapsed/refractory multiple myeloma progression-free for ...

Multiple myeloma is a type of blood cancer caused by a buildup of abnormal plasma cells in the bone marrow. As the abnormal plasma cells accumulate, they crowd out healthy cells and cause symptoms ...

Oral presentation of CARTITUDE-1 study data showcases long-term outcomes after a single infusion of CARVYKTI® with one-third of patients with relapsed/refractory multiple myeloma progression-free for ...